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Abstract 
Mammalian glutaminases are encoded by two 
paralogous genes, Gls and Gls2, presumably derived 
by gene duplication of a common ancestor. Each 
gene codes for two different isoforms. The two 
transcripts of Gls2, named GAB and LGA, arise 
through a surrogate promoter usage mechanism. In 
certain types of malignancies, such as glioblastoma 
and liver cancers, expression of GLS2 gene is 
repressed by promoter hypermethylation, which 
could contribute to the malignant process. The 
finding that ectopic expression of GLS2 could 
inhibit proliferation of these tumors led to the 
hypothesis that this isoenzyme, a transcriptional 
target of TP53, might play a role as tumor 
suppressor, in opposition to  
GLS, regulated by oncogenes and associated to 
tumorigenesis. However, recent findings indicate 
that GLS2 is upregulated in some types of cancer 
(NMYC-amplified neuroblastoma, cervical, colon 
and lung cancers) and this upregulation 
paradoxically correlates with poor clinical outcomes. 
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Figure 1. Genomic structure of human glutaminase GLS2 gene and alternative transcripts GAB and LGA. Introns are depicted 
as solid light blue lines and exons as numbered dark blue boxes. Dashed red or dotted black lines indicate the exons involved in 
the generation of GAB and LGA transcripts, respectively (Campos-Sandoval et al., 2015). 
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Description 
Human GLS2 gene is located on chromosome 12 
(Aledo et al., 2000). It is composed of 18 exons and 
spans approximately 18 kb (Pérez-Gómez et al., 
2003). The gene resides on the minus strand. It starts 
at 56470944 and ends at 56488414 from pter (NCBI, 
Gene ID 27165). 
Transcription 
Two GLS2 transcripts coding for functional proteins 
have been described: a long canonical one 
containing all 18 exons (GAB), cloned from a human 
breast cancer cell line (Gómez-Fabre et al., 2000) 
and a short variant (LGA), first characterized in rat 
liver (Smith and Watford, 1990; Chung-Bok et al., 
1997) and lacking the first exon (Martèn-Rufián et 
al., 2012). LGA transcript arises by a combination of 
two mechanisms of transcriptional regulation: 
alternative transcription initiation and alternative 
promoter. Its transcription start site is located at 3-
end of the first intron of GLS2 gene. Other non-
coding transcripts, containing premature stop 
codons, have been isolated (Martèn-Rufián et al., 
2012).  
The molecular basis for GLS2 regulation is now 
starting to be uncovered. GLS2 has been identified 
as a transcriptional target of tumor suppressor TP53 
that mediates its new revealed functions in tumor 
metabolism and antioxidant defense, under both 
non-stressed and stressed conditions. This tumor 
suppressor directly associates with response 
elements in the GLS2 promoter (Hu et al., 2010; 
Suzuki et al., 2010). Cells with heightened GLS2 
levels showed increased production of glutamate and 
alpha-ketoglutarate, which resulted in enhanced 
oxydative phosphorylation, higher GSH/GSSG 
ratios and decreased reactive oxygen species (ROS) 
levels, which provided protection against ROS 
induced apoptosis (Hu et al., 2010; Suzuki et al., 
2010). Two other transcription factors belonging to 
the TP53 family, TP73 and TP63, also drive the 
expression of GLS2 during neuronal differentiation  
of neuroblastoma cells after induction with retinoic 
acid (Velletri et al., 2013) and during epidermal 
differentiation and in cancer cells exposed to 
oxidative stress (Giacobbe et al., 2013), respectively. 
The GLS2 downregulation observed in liver and 
colon cancer cell lines and in hepatocellular 
carcinoma has been attributed to its promoter 
hypermethylation, a mechanism that has been 
proposed as a marker to identify novel tumor 
suppressor genes. Chemical demethylation treatment 
increased the GLS2 mRNA levels in these cells 
(Zhang et al., 2013; Liu et al., 2014). This 
mechanism is also responsible for the GLS2 
silencing detected in highly malignant 
glioblastomas, and occurs regardless of their TP53 
status (Szeliga et al., 2016). Other factors that 
regulate GLS2 expression are the MYCN 
oncoprotein (v-myc avian myelocytomatosis viral 
oncogene neuroblastoma derived homolog, encoded 
by MYCN gene) and the NR5A2 (nuclear receptor 
subfamily 5 group A member 2), also known as 
LRH-1 (liver receptor homolog 1). MYCN, an 
essential MYC family member, directly activates 
GLS2 transcription in MYCN-amplified 
neuroblastoma cells. Depletion of MYCN 
expression by short hairpin RNA caused a 
pronounced decrease in GLS2 (but not GLS) levels 
in these cells. Conversely, inhibition of TP53 had no 
effect on GLS2 induction (Xiao et al., 2015). In 
hepatoma cells, GLS2 is subjected to direct 
transcriptional regulation by NR5A2. Silencing of 
NR5A2 mediated by small interfering RNA reduced 
GLS2 transcript and protein levels (Xu et al., 2016). 
Long non-coding RNA (lncRNA) and microRNAs 
(miRNAs) are also implicated in GLS2 regulation. 
The lncRNA urothelial carcinoma-associated 1 ( 
UCA1) regulates GLS2 expression levels through 
interfering with MIR16-1, which binds to the 3'-UTR 
(untranslated region) of GLS2 mRNA (Li et al., 
2016). 
Pseudogene 




Figure 2. Schematic diagram of GLS2 isoforms showing the localization of predicted domains and motifs by sequence analysis 
(Márquez et al., 2016). 
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Description 
Purification:  the first attempts to purify liver-type 
glutaminase from rat liver only yielded partial 
purifications: 15-fold (Huang and Knox, 1976) and 
60-fold (Patel and McGivan, 1984). Unlike kidney-
type glutaminase (KGA), the liver isoenzyme does 
not polymerize in the presence of phosphate-borate 
buffer (Huang and Knox, 1976). This different 
behaviour, together with its greater instability in 
tissue homogenates and diluted preparations, made 
this isoenzyme more difficult to purify than KGA. In 
fact, its purification to near homogeneity was not 
achieved until almost two decades later than KGA 
purification. Heini et al. (1987) purified rat LGA 
400-fold, while Smith and Watford (1988) reported 
a 600-fold purification, with specific activities of 30-
50 μmol/min per mg protein. Human GAB 
isoenzyme has been expressed as a recombinant 
protein in baculovirus system and purified by 
affinity chromatography with a specific activity of 
18 μmol/min per mg protein (Campos-Sandoval et 
al., 2007).  
Structure:  human GAB transcript (ORF: 1809 nt) 
codes a 602-residues protein, with a predicted 
molecular mass of 66.3 kDa. Human LGA transcript 
(ORF: 1698 nt) codes a 565-residues protein, with a 
predicted molecular mass of 62.5 kDa. The precursor 
of human LGA isoform lacks the first 61 residues of 
GAB precursor (coded by exon 1), but it displays an 
additional extension of 24 novel residues at the N-
terminus coded by an alternative first exon. This 
extension and the first six amino acids coded by exon 
2 are not present in its rat and mouse counterparts 
(Martèn-Rufián et al., 2012). GLS2 contains a 
central glutaminase domain of approximately 300 
residues, which belongs to the beta 
lactamase/transpeptidase-like superfamily, and three 
ankyrin repeats at the C-terminal region (Pasquali et 
al., 2017). The ankyrin repeats are protein-protein 
interaction modules of 33 residues that have been 
found in many important proteins such as 
transcriptional factors, cell cycle regulators, 
cytoskeletal organizers, etc. (Sedgwick and 
Smerdon, 1999; Mosavi et al., 2004). At its C-
terminal end there is a consensus sequence of four 
residues required for specific interaction with PDZ 
(postsynaptic density protein, disc large, zona 
occludens) proteins (Olalla et al., 2001). The N-
terminal end (first 14 residues) of GAB precursor 
contains a putative mitochondrial import 
presequence (Gómez-Fabre et al., 2000). It is worth 
mentioning the presence of a consensus LXXLL 
motif of interaction with nuclear receptors at N-
terminal region of GLS2 (Olalla et al., 2002). It is in 
the regions involved with organelle targeting (exon 
1) and protein-protein interactions (exon 18) that the 
main differences between GAB and kydney-type 
glutaminase reside (Pérez-Gómez et al., 2003). 
Studies on processing and molecular structure of 
native GLS2 protein are lacking. An apparent 
subunit molecular mass of 57-58 kDa for the rat liver 
isoform was determined by denaturing gel 
electrophoresis of purified protein (Heini et al., 
1987; Smith and Watford, 1988). Sequencing by 
Edman degradation of the mature form of human 
GAB expressed in baculovirus system showed 
cleavage between amino acids 38-39 and 39-40 of 
the deduced protein sequence. These cleavages are 
consistent with known substrate sites for the 
mitochondrial processing peptidase (MPP), having 
an Arg residue at position -2 or -3. Nevertheless, 
processing in baculovirus system may somehow 
differ from the native processing in mammals 
(Campos-Sandoval et al., 2007). The molecular mass 
(Mr) of native GLS2 has not been determined 
accurately. Smith and Watford (1988) reported an 
Mr of ≥ 300000 from HPLC gel filtration but 
obtained a value of 162000 by sucrose gradient 
centrifugation, regardless of phosphate 
concentration (5 or 100 mM).  
Kinetic properties:  the distinct kinetic behavior of 
mammalian kydney-type and liver-type isoenzymes 
was first noted by Krebs (1935). In contrast with 
kydney-type isoenzyme, the rat liver-type 
glutaminase showed a lower dependence on the 
activator inorganic phosphate (Pi), lower affinity for 
the substrate glutamine, lack of inhibition by 
glutamate (up to 50 mM) and a requirement for 
ammonia as an obligatory activator (Verhoeven et 
al., 1983; Patel and McGivan, 1984; Smith and 
Watford, 1988). The only human GLS2 protein 
characterized in a purified form is the recombinant 
GAB expressed in insect cells. It showed an 
allosteric behavior (Hill index of 2.7) with low 
affinity for glutamine (S0.5 values of 32 and 64 mM 
for high (150 mM) and low (5 mM) Pi, respectively), 
and low dependence for Pi as expected for a GLS2 
isoenzyme. Surprisingly, GAB was inhibited by 
glutamate, a characteristic only shown by GLS 
isoforms, with an IC50 value of 50 mM at low Pi 
concentrations (5 mM) and suboptimal glutamine 
concentration (20 mM), and scarcely activated by 
ammonia (Campos-Sandoval et al., 2007).  
Post-translational modifications:  several 
acetylated and succinylated lysine residues have 
been identified in GLS2 by large-scale proteomic 
approaches (Rardin et al., 2013; Park et al., 2013). 
Expression 
The classical pattern of glutaminase expression first 
established that GLS2 isoforms were restricted to 
postnatal liver, while GLS isoforms were widely 
distributed in most nonhepatic tissues (Curthoys and 
Watford, 1995). Recent findings have extended the 
range of GLS2 expression to other extrahepatic 
tissues such as brain, pancreas, cells of immune 
system and tumor cells (Aledo et al., 2000; Castell et 
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al., 2004; Gómez-Fabre et al., 2000; Pérez-Gómez et 
al., 2005). Experimental evidences now support that 
both glutaminase genes are coexpressed in some 
tissues as well as in many cell types. Thus, GLS2 co-
localized with KGA in numerous cells throughout 
the brain (Olalla et al., 2002; Cardona et al., 2015). 
Both GLS2 and GLS transcripts were also found to 
be co-expressed in liver and brain of rat, mouse and 
human (Martèn-Rufián et al., 2012). Simultaneous 
expression of GLS and GLS2 isoforms were also 
confirmed for several human cancer cells at the 
transcriptome and proteome levels (Turner and 
McGivan, 2003; Pérez-Gómez et al., 2005). In 
different types of cancer, such as bladder, colon and 
lung cancer, GLS2 is considerably overexpressed 
compared with normal tissues (Saha et al., 2019). 
Localisation 
Although glutaminase has long been considered 
predominantly a mitochondrial enzyme (Curthoys 
and Watford, 1995), a differential localization for 
glutaminase was found in neurons using isoform-
specific antibodies (Campos et al., 2003): while 
KGA was present in mitochondria, a Gls2-encoded 
isoform - most probably GAB - was found in nuclei 
where it was catalytically active (Olalla et al., 2002). 
Function 
GLS2 (E.C. 3.5.1.2.) catalyzes the hydrolytic 
deamidation of L-glutamine to form L-glutamate and 
ammonium, the first step of glutaminolysis. In liver, 
GLS2 reaction provides substrates for 
gluconeogenesis and urea synthesis (Watford, 1993). 
A role of GLS2 in neuronal differentiation has been 
recently reported (Velletri et al., 2013). In some 
cancer cells, GLS2 may play a role as tumor 
suppressor, in opposition to GLS, regulated by 
oncogenes and associated to tumorigenesis. GLS2 
overexpression in glioblastoma cell lines caused a 
reversion of their transformed phenotype (Szeliga et 
al., 2009). This is in agreement with the loss of GLS2 
expression in hepatocellular carcinomas (Suzuki et 
al., 2010) and brain tumors (Szeliga et al., 2005). 
However, this behavior of GLS2 is not universal, as 
there are some types of cancer - cervical and lung 
cancers, NMYC-amplified neuroblastoma - where 
GLS2 expression is upregulated and this 
upregulation is associated with therapeutic 
resistance and poor clinical outcomes (Xiang et al., 
2013; Xiang et al., 2015; Saha et al., 2019).  
Interacting partners:  the first protein-interacting 
partners of GLS2 were discovered by two-hybrid 
genetic screening of a human brain cDNA library, 
using the C-terminal region of GLS2 as bait. Two 
PDZ domain-containing proteins were isolated: 
SNTA1 (alpha 1-syntrophin) and TAX1BP3 (Tax1-
binding protein 3, also known as Tax-interacting 
protein 1 (TIP-1) or glutaminase-interacting protein 
(GIP)). The C-terminal end of human GLS2, -
ESMV, matches the consensus sequence X-Ser/Thr-
X-Val required for interaction with PDZ proteins 
(Olalla et al., 2001). A dissociation constant of 1.66 
μM was determined for the GLS2-GIP binding, 
which indicates a moderate affinity suitable for 
regulatory functions (Banerjee et al., 2008).  
Two recent findings have revealed the important role 
that GLS2 plays in tumor suppression through its 
interactions with other proteins in a glutaminase 
activity independent manner. GLS2 binds through its 
C-terminal region to RAC1 (Rac family small 
GTPase 1), a critical promoter of metastasis 
frequently activated in several types of cancer, and 
inhibits its activation by guanine-nucleotide 
exchange factors (GEFs). Thus, as a direct target of 
TP53, GLS2 mediates TP 53's function in metastasis 
suppression (Zhang et al., 2016). GLS2 also binds to 
and stabilizes DICER1, a key component of the 
microRNAs processing machinery, promoting 
MIR34A maturation. Upregulation of this miRNA 
represses metastasis in hepatoma cells through 
expression inhibition of SNAI1 (snail family 
transcriptional repressor 1), a transcriptional 
repressor of cadherin 1 (CDH1, also known as E-
cadherin) (Kuo et al., 2016). 
Implicated in 
Drug inhibitors:  in contrast to GLS, little effort has 
been devoted to the search for specific GLS2 
inhibitors. In a recent study, Lee and coworkers have 
described several alkyl benzoquinones isolated from 
Ardisia virens or Ardisia kusukuensis that 
selectively inhibit GAB over GLS and display 
antitumor activity (Lee et al., 2014). 
Bladder cancer 
GLS2 is overexpressed in bladder cancer (Li et al., 
2015; Saha et al., 2019). Urothelial carcinoma-
associated 1 (UCA1) is a lncRNA which has been 
linked to bladder cancer progression and resistance 
to drugs. Expression levels of UCA1 and GLS2 
positively correlated in these tumor cells. UCA1 
possesses a binding site for miRNA-16, a repressor 
of GLS2 expression.  
Overexpression of UCA1 resulted in enhanced 
GLS2 mRNA and protein levels and decreased 
levels of miRNA-16. Thus, UCA1 reduced ROS 
generation by acting as a natural molecular sponge 
to block the tumor suppressor function of miR-16 (Li 
et al., 2015). 
Cervical Carcinoma 
Expression of GLS2 is significantly elevated in 
cervical carcinoma of radioresistant patients 
compared with that in radiosensitive patients. 
Silencing of GLS2 expression in radioresistant 
cancer cells caused downregulation of GSH, NADH 
and NADPH levels, leading to enhanced levels of 
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ROS and sensitivity to ionizing radiation (Xiang et 
al., 2013). 
Glioblastoma 
GLS2 expression is downregulated in highly 
malignant glioblastoma (Szeliga et al., 2005; Szeliga 
et al., 2009). One of the mechanisms involved in this 
gene silencing was recently demonstrated to be 
promoter methylation and not related to the TP53 
status (Szeliga et al., 2016). Human glioblastoma 
T98G cells stably transfected with the full GAB 
cDNA coding sequence showed a reversion of their 
malignant phenotype, including a marked inhibition 
in growth and proliferation (Szeliga et al., 2009), 
downregulation of the expression of DNA-repair 
gene MGMT and sensitization to alkylating agents 
(Szeliga et al., 2012). ROS generation by treatment 
with oxidizing agents synergized with GAB 
overexpression in T98G glioma cells to suppress 
their malignant properties, including the reduction of 
cellular mobility (Martèn-Rufián et al., 2014). This 
increased sensitivity of GAB-transfected cells to 
oxidative stress is related to the inhibition of 
PI3K/AKT pathway (Majewska et al., 2019). 
Hepatocellular Carcinoma 
GLS2 has been identified as a target of TP53 tumor 
suppressor gene (Hu et al., 2010; Suzuki et al., 2010) 
and is frequently downregulated or repressed in 
some types of cancer, like human hepatocellular 
carcinoma (Yuneva et al., 2012). It is remarkable that 
GLS2 transcripts were almost absent or significantly 
decreased in hepatocellular carcinomas compared to 
normal liver tissue, where GLS2 is abundantly 
expressed (Suzuki et al., 2010). A switch from GLS2 
to GLS expression was detected in HCC samples 
compared with surrounding nontumor liver tissue 
(Xiang et al., 2015). GLS2 downregulation was 
correlated to its promoter hypermethylation. Ectopic 
expression of GLS2 led to cancer cell growth 
inhibition and cell cycle arrest (Zhang et al., 2013). 
The negative regulation that GLS2 exerts on the 
PI3K/AKT signaling contributes greatly to its tumor 
suppressive activity in HCC (Liu et al., 2014). GLS2 
also mediates TP53 function in metastasis 
suppression in HCC through directly inhibiting 
RAC1, which is central to processes involved in 
malignant transformation (Zhang et al., 2016), and 
stabilizing DICER1, which represses SNAIL, a 
transcriptional repressor of cadherin 1, through miR-
34a upregulation (Kuo et al., 2016). Moreover, 
GLS2 has been proposed, together with DUOX1 
(dual oxidase 1) and FBP1 (fructose-bisphosphatase 
1), as prognostic markers for HCC patients' survival 
(Chen et al., 2016). 
Colon cancer 
As in HCC; Zhang and coworkers reported the 
downregulation of GLS2 expression in human colon 
cancer cell lines via promoter hypermethylation. 
Demethylation treatment increased GLS2 mRNA 
levels. In addition, ectopic overexpression of GLS2 
induced cell cycle arrest at G2/M phase through 
negative regulation of the CDC25C (cell division 
cycle 25C) protein phosphatase by phosphorylation 
on Ser 216. Reduced GLS2 mRNA levels were also 
observed in 5 cancerous samples from patients with 
colon cancer (Zhang et al., 2013). Nevertheless, 
other authors have reported a considerable 
overexpression of GLS2 in colon cancer samples 
with respect to normal tissue using expression data 
extracted from several databases (Giacobbe et al., 
2013; Saha et al., 2019). 
Lung cancer 
Inhibition of GLS2 by a series of alkyl 
benzoquinones or RNA silencing significantly 
reduced proliferation of lung cancer cell lines (Lee 
et al., 2014). 
Neuroblastoma 
In MYCN-amplified neuroblastomas, GLS2 
expression is significantly elevated, correlating with 
poor prognosis. MYCN directly activates GLS2 but 
not GLS expression. A Myc response element is 
found within the first intron of GLS2 gene. 
Knockdown of GLS2 expression caused glutamine-
dependent anaplerosis inhibition, decreased aerobic 
glycolysis due to thioredoxin-interacting protein 
(TXNIP) activation, and lowered GSH levels, 
resulting in proliferation inhibition of these tumors 
both in vitro and in vivo (Xiao et al., 2015). 
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